July 13, 2018 – By Jacob Reddy
Morgan Stanley decreased Old Line Bancshares Inc (OLBK) stake by 28.02% reported in 2018Q1 SEC filing. Morgan Stanley sold 12,287 shares as Old Line Bancshares Inc (OLBK)’s stock rose 8.59%. The Morgan Stanley holds 31,560 shares with $1.04 million value, down from 43,847 last quarter. Old Line Bancshares Inc now has $589.62 million valuation. The stock decreased 0.36% or $0.125 during the last trading session, reaching $34.735. About 41,061 shares traded. Old Line Bancshares, Inc. (NASDAQ:OLBK) has risen 23.18% since July 13, 2017 and is uptrending. It has outperformed by 10.61% the S&P500. Some Historical OLBK News: 26/04/2018 – Old Line Bank Adds Montgomery County Lending Expert to Growing Team; 17/04/2018 – SNB Rewinds Currency Clock as Old Line in Sand Neared (Correct); 16/04/2018 News On Bay Bancorp Inc. (BYBK) Now Under OLBK
Analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report $1.21 EPS on August, 2.They anticipate $0.33 EPS change or 37.50% from last quarter’s $0.88 EPS. ANIP’s profit would be $14.26M giving it 14.60 P/E if the $1.21 EPS is correct. After having $1.23 EPS previously, ANI Pharmaceuticals, Inc.’s analysts see -1.63% EPS growth. The stock decreased 0.86% or $0.61 during the last trading session, reaching $70.67. About 22,543 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 31.37% since July 13, 2017 and is uptrending. It has outperformed by 18.80% the S&P500. Some Historical ANIP News: 07/05/2018 – ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax; 18/04/2018 – ANIP SAYS FDA APPROVES MORPHINE SULFATE ORAL SOLUTION; 27/04/2018 – ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax; 18/04/2018 – ANI PHARMACEUTICALS INC – RECEIVED APPROVAL FROM U.S. FDA OF ITS ANDA FOR MORPHINE SULFATE ORAL SOLUTION 10MG/5ML, 20MG/5ML AND 100MG/5ML; 08/05/2018 – ANI Pharmaceuticals Sees 2018 Adj EPS $5.43-Adj EPS $6.08; 07/05/2018 – ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/lmpax; 27/04/2018 – ANI Pharmaceuticals to Buy Generic Products, Assets From Amneal/Impax; 27/04/2018 – ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/lmpax; 03/04/2018 IDT AUSTRALIA LTD IDT.AX – TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC; 27/04/2018 – ANI PHARMACEUTICALS – UPON DEAL CLOSING , ANI TO BUY PRODUCT PORTFOLIO CONSISTING OF 5 APPROVED GENERIC ANDAS, 1 PIPELINE PRODUCT, ERYTHROMYCIN IR TABLETS
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $832.95 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 35335 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.
Among 2 analysts covering ANI Pharmaceuticals (NASDAQ:ANIP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ANI Pharmaceuticals had 2 analyst reports since February 28, 2018 according to SRatingsIntel. Canaccord Genuity maintained the shares of ANIP in report on Wednesday, February 28 with “Buy” rating. Cantor Fitzgerald initiated ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) on Monday, June 11 with “Buy” rating.
More news for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) were recently published by: Nasdaq.com, which released: “Market Trends Toward New Normal in EnviroStar, Rowan Companies, Del Taco Restaurants, ANI Pharmaceuticals …” on June 25, 2018. Investorplace.com‘s article titled: “4 Undervalued MedTech Stocks to Consider Amid Volatility” and published on June 19, 2018 is yet another important article.
Investors sentiment increased to 1.43 in Q1 2018. Its up 0.34, from 1.09 in 2017Q4. It increased, as 12 investors sold ANI Pharmaceuticals, Inc. shares while 42 reduced holdings. 37 funds opened positions while 40 raised stakes. 6.72 million shares or 7.48% more from 6.25 million shares in 2017Q4 were reported. Mckinley Carter Wealth Serv holds 0.01% or 650 shares in its portfolio. Mangrove Prns holds 376,314 shares or 1.43% of its portfolio. 14,800 are owned by Swiss Commercial Bank. Wells Fargo & Mn reported 13,774 shares stake. California State Teachers Retirement Systems reported 12,219 shares. Perigon Wealth Management Limited Co invested 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Aperio Lc accumulated 0% or 4,780 shares. Advisory Serv Networks Lc owns 47 shares. Citadel Advsrs Ltd Co holds 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) or 4,903 shares. Georgia-based Cornercap Inv Counsel Inc has invested 0.21% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Consonance Lp has invested 0.76% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Cubist Systematic Strategies Ltd Co reported 0.06% stake. State Of Tennessee Treasury Department accumulated 6,404 shares. 6,981 were reported by Diker Mgmt Ltd Co. Northern Corp owns 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 112,096 shares.
Since March 1, 2018, it had 0 buys, and 10 insider sales for $18.16 million activity. $439,047 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was sold by RAYNOR DANIEL on Thursday, March 15. On Thursday, March 1 the insider PRZYBYL ARTHUR sold $1.47 million. 38,236 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares with value of $2.38 million were sold by MARSHBANKS TRACY. Schrepfer Robert W sold $1.77M worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) on Thursday, March 1. Marken James G. also sold $258,640 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares.
More news for Old Line Bancshares, Inc. (NASDAQ:OLBK) were recently published by: Nasdaq.com, which released: “Old Line Bank to Host Family Carnival During Celebrate Damascus Festival” on July 13, 2018. Nasdaq.com‘s article titled: “Old Line Bank is Gearing Up in Response to Continued Loan Growth” and published on July 02, 2018 is yet another important article.
Since January 29, 2018, it had 13 insider buys, and 25 sales for $6.89 million activity. Another trade for 1,000 shares valued at $34,230 was bought by Deadrick Stephen J. $60,971 worth of Old Line Bancshares, Inc. (NASDAQ:OLBK) was sold by HOVDE ERIC D on Wednesday, May 23. 1,000 shares were sold by DENT JAMES F, worth $31,653. Shares for $200,395 were sold by Thomas Joseph. 1,500 shares were sold by Clifford James R SR, worth $47,906. Semanie Mark A bought $50,678 worth of stock. Another trade for 1,000 shares valued at $34,560 was made by Suit John M II on Friday, June 15.
Analysts await Old Line Bancshares, Inc. (NASDAQ:OLBK) to report earnings on August, 3. They expect $0.54 EPS, up 50.00% or $0.18 from last year’s $0.36 per share. OLBK’s profit will be $9.17 million for 16.08 P/E if the $0.54 EPS becomes a reality. After $0.48 actual EPS reported by Old Line Bancshares, Inc. for the previous quarter, Wall Street now forecasts 12.50% EPS growth.
Among 3 analysts covering Old Line Bancshares (NASDAQ:OLBK), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Old Line Bancshares had 3 analyst reports since January 24, 2018 according to SRatingsIntel. The firm has “Hold” rating given on Monday, February 26 by Keefe Bruyette & Woods. The stock has “Buy” rating by Sandler O’Neill on Wednesday, January 24. The firm has “Buy” rating given on Wednesday, March 28 by Stephens.
Morgan Stanley increased Sothebys (NYSE:BID) stake by 66,478 shares to 288,097 valued at $14.78 million in 2018Q1. It also upped Audiocodes Ltd (NASDAQ:AUDC) stake by 107,486 shares and now owns 1.79 million shares. Xperi Corp was raised too.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.